GLP-1 receptor agonists are a class of prescription medications that have transformed weight management and diabetes treatment. Originally developed for type 2 diabetes, they are now FDA-approved for chronic weight management — helping patients achieve 15-22% body weight loss in clinical trials. Here’s how they work, what medications are available, and what you need to know before starting treatment.
What Is GLP-1?
GLP-1 (glucagon-like peptide-1) is a hormone your body naturally produces in the small intestine after you eat. It’s part of a family called incretins — gut hormones that help regulate blood sugar, appetite, and digestion.
When you eat a meal, your intestines release GLP-1 which does several things simultaneously:
- Signals your pancreas to produce more insulin (only when blood sugar is elevated)
- Tells your brain you’re full by activating satiety centers in the hypothalamus
- Slows stomach emptying so food stays in your stomach longer, keeping you feeling full
- Reduces glucagon production, which lowers blood sugar
The problem? Natural GLP-1 is broken down by an enzyme called DPP-4 within 2-3 minutes. It barely has time to work before it’s destroyed. GLP-1 medications solve this by using synthetic versions that resist DPP-4 degradation and last for days to a full week per dose.
- Produced after eating
- Lasts only 2-3 minutes
- Destroyed by DPP-4 enzyme
- Injected once weekly (or daily for some)
- Resist DPP-4 breakdown
- Active for days, amplifying the natural effect
How GLP-1 Medications Produce Weight Loss
GLP-1 medications work through three simultaneous pathways that together produce significant, sustained weight loss:
1. Brain: Appetite Suppression
GLP-1 medications cross the blood-brain barrier and activate receptors in the hypothalamus — the brain’s hunger control center. This suppresses appetite signals, reduces cravings (especially for high-fat and high-sugar foods), and creates a feeling of satiety that persists throughout the day. Patients consistently report that they simply think about food less.
2. Stomach: Delayed Emptying
GLP-1 slows the rate at which food leaves your stomach and enters the small intestine — a process called gastric emptying. When food stays in your stomach longer, you feel full after eating less and stay satisfied between meals. This is one reason smaller portions feel more satisfying on GLP-1 treatment.
3. Pancreas: Blood Sugar Regulation
GLP-1 enhances glucose-dependent insulin secretion — meaning your pancreas produces more insulin only when blood sugar is actually elevated. It also suppresses glucagon (a hormone that raises blood sugar). This dual action improves metabolic health, reduces insulin resistance, and addresses the underlying metabolic dysfunction that drives weight gain.
4. Beyond Weight Loss
Clinical research has uncovered benefits beyond weight management: cardiovascular protection (Wegovy is FDA-approved to reduce heart attack and stroke risk), reduced inflammation, improved cholesterol profiles, lower blood pressure, and potential benefits for liver health and kidney function. GLP-1 medications may be treating more than obesity — they may be treating the metabolic syndrome that underlies it.
What the Clinical Trials Show
GLP-1 medications have been studied in some of the largest weight management clinical trials ever conducted. Here are the headline results:
| Medication | Active Ingredient | Avg. Weight Loss | Trial Duration | FDA Approved For |
|---|---|---|---|---|
| Wegovy | Semaglutide 2.4mg | ~15% body weight | 68 weeks | Weight loss + Cardiovascular |
| Zepbound | Tirzepatide 15mg | ~22% body weight | 72 weeks | Weight loss + Sleep apnea |
| Ozempic | Semaglutide 1mg | ~10-14% body weight | 68 weeks | Type 2 diabetes |
| Mounjaro | Tirzepatide 15mg | ~20% body weight | 72 weeks | Type 2 diabetes |
| Saxenda | Liraglutide 3mg | ~5-8% body weight | 56 weeks | Weight loss |
| Rybelsus | Oral semaglutide 14mg | ~5-10% body weight | 52 weeks | Type 2 diabetes (oral) |
Sources: STEP trials (semaglutide), SURMOUNT trials (tirzepatide), SCALE trials (liraglutide). Individual results vary.
GLP-1 vs. Dual GLP-1/GIP Agonists
There are now two generations of incretin-based weight loss medications:
First generation — GLP-1 receptor agonists: Semaglutide (Ozempic, Wegovy) and liraglutide (Saxenda) target only the GLP-1 receptor. They produce significant weight loss (15% average) and have the longest real-world track record, with semaglutide in clinical use since 2017.
Second generation — Dual GLP-1/GIP agonists: Tirzepatide (Zepbound, Mounjaro) activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. The dual mechanism produces greater weight loss (~22%) and appears to offer enhanced metabolic benefits, including better insulin sensitivity and potentially improved bone health compared to GLP-1 alone.
The next frontier includes triple agonists targeting GLP-1, GIP, and glucagon receptors simultaneously — currently in late-stage clinical trials with weight loss results exceeding 25%.
- Ozempic, Wegovy, Rybelsus
- ~15% weight loss
- Longest safety track record
- Zepbound, Mounjaro
- ~22% weight loss
- Enhanced metabolic benefits
Who Is Eligible for GLP-1 Medications?
FDA-approved GLP-1 medications for weight management (Wegovy, Zepbound) are indicated for adults who meet one of these criteria:
BMI ≥ 30
Adults with a BMI of 30 or higher (classified as obesity) are eligible regardless of other health conditions. This is the primary indication for weight management GLP-1s.
BMI ≥ 27 + Comorbidity
Adults with a BMI of 27 or higher who also have at least one weight-related condition — such as type 2 diabetes, high blood pressure, high cholesterol, or obstructive sleep apnea — are also eligible.
Type 2 Diabetes
Ozempic and Mounjaro are FDA-approved specifically for type 2 diabetes management, regardless of weight loss goals. They improve blood sugar control while also producing weight loss as a secondary benefit.
Who Should NOT Take GLP-1s
GLP-1 medications are contraindicated for patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They are not approved for use during pregnancy or breastfeeding.
Brand-Name vs. Compounded GLP-1 Medications
When you hear about GLP-1 medications, there are two distinct categories:
Brand-name (FDA-approved): Ozempic, Wegovy, Zepbound, Mounjaro, Saxenda, and Rybelsus are manufactured under strict FDA oversight by Novo Nordisk and Eli Lilly. They have been tested in large clinical trials involving tens of thousands of patients. What you inject is exactly what was studied.
Compounded: Compounded semaglutide and tirzepatide are mixed by compounding pharmacies using the same active ingredient but in formulations that have not been reviewed by the FDA for safety, efficacy, or manufacturing quality. They are legally available when brand-name versions are on the FDA shortage list, and are typically 50-80% cheaper.
The key question for patients: is the cost savings worth the tradeoff in quality assurance? Our reviews evaluate providers on medication sourcing transparency, including whether they use 503A or 503B compounding pharmacies, whether they provide Certificates of Analysis, and whether they disclose their pharmacy partners.
- FDA-approved safety and efficacy
- Exact formulation from clinical trials
- Pre-filled pens — no dosing errors
- Insurance may cover
- Not FDA-approved
- Dosing errors possible (vial + syringe)
- Variable quality by pharmacy
- May use different salt forms
Learn more: Understanding 503B Compounding Pharmacies | Known GLP-1 Side Effects
What to Expect on GLP-1 Treatment
Week 1-4: Most patients notice reduced appetite within the first 1-2 weeks. Nausea is common during dose escalation. Start with the lowest dose and titrate up slowly.
Month 1-3: Meaningful weight loss begins — typically 5-10 lbs in the first month. Side effects generally improve as the body adjusts. Patients report thinking about food significantly less.
Month 3-6: Doses increase to therapeutic levels. Weight loss accelerates. Most patients are losing 1-2 lbs per week consistently. Energy levels often improve as metabolic health improves.
Month 6-12: The full effect of GLP-1 treatment is typically reached between 9-15 months. Clinical trials show average weight loss of 15-22% of total body weight at this stage.
Long-term: GLP-1 medications treat the biological drivers of obesity — they don’t cure them. Most patients who discontinue regain a significant portion of weight within 12 months, similar to stopping blood pressure or cholesterol medication. Long-term use is typically necessary to maintain results.
Ready to Compare GLP-1 Providers?
We’ve independently reviewed and scored 70+ GLP-1 telehealth providers across safety, clinical quality, trust, and value — so you can find the right program for your needs.
Sources: STEP clinical trials (Novo Nordisk), SURMOUNT clinical trials (Eli Lilly), SCALE trials, Cleveland Clinic GLP-1 overview, NEJM GLP-1 Receptor Agonists review, StatPearls GLP-1 pharmacology, FDA prescribing labels for Ozempic, Wegovy, Zepbound, Mounjaro, Saxenda, and Rybelsus.
Disclaimer: This page is for informational purposes only and does not constitute medical advice. GLP-1 medications are prescription drugs. Always consult your doctor before starting any new medication.
